Uzbekistan is seeking to position itself as a commercial bridge between Indian healthcare manufacturers and the markets of the former Soviet Union, as officials and private-sector organisers push a plan to channel pharmaceutical, over-the-counter and nutraceutical trade through Central Asia into the Commonwealth of Independent States.
The effort, supported by Uzbekistan’s Ministry of Health alongside the industry platform Nutrify Today and the exhibition organiser Pharma Eurasia, reflects a broader attempt to create a more structured corridor connecting India’s manufacturing strength with consumer-health demand across Eurasia.
Rather than treating the CIS as a fragmented set of difficult export destinations, proponents of the initiative argue that a coordinated trade route through Uzbekistan could give international suppliers a clearer pathway into a regional market of more than 180 million people across the Eurasian Economic Union and neighbouring states.
For Indian companies in particular, the timing is notable. Across several CIS markets, demand for preventive healthcare products including vitamins, botanicals, immunity supplements and condition-specific nutrition has been rising steadily. At the same time, pharmacy retail is becoming more consolidated and professionalised, shifting the market toward suppliers capable of meeting stricter regulatory standards and supporting large-scale retail distribution.
Kazakhstan offers one illustration of that transition. Research from regional pharmaceutical market analysts indicates that chain pharmacies accounted for more than 60 per cent of the country’s retail pharmaceutical market by early 2025. Uzbekistan is following a similar trajectory, with pharmacy chains now representing more than 40 per cent of retail sales, as modern distribution networks expand and independent outlets gradually lose share.
For international manufacturers, that consolidation alters the economics of market entry. Historically, CIS markets required dealing with thousands of fragmented retail points. Increasingly, access is determined by relationships with a smaller number of large pharmacy chains, distributors and retail groups that demand stronger product documentation, reliable supply chains and regulatory compliance.
Russia remains the largest and most commercially consequential market in the region. Industry data suggest the Russian pharmaceutical market reached roughly 2.85 trillion roubles in 2024, growing by about 10 per cent year on year. The structure of retail distribution has also shifted: the country’s ten largest pharmacy chains now control nearly half of pharmaceutical retail sales.
Digital channels are adding another dimension to the market. Online pharmacy and healthcare e-commerce platforms have been expanding rapidly across Russia and neighbouring markets, creating hybrid retail models in which consumers increasingly discover products online before purchasing through physical pharmacies or digital marketplaces.
Together, these developments are reshaping opportunities for supplement ingredient suppliers and finished-product manufacturers. In more consolidated pharmacy environments, buyers tend to prioritise products that carry robust quality documentation and clinical positioning rather than purely trend-driven wellness claims.
As a result, categories such as immunity support, digestive health, women’s health, healthy ageing, metabolic health and specialised nutrition are gaining traction across pharmacy shelves in the region. The growth of preventive healthcare awareness — accelerated by the pandemic and demographic ageing — has also pushed consumers toward regular supplementation rather than episodic wellness purchases.
For ingredient manufacturers, the opportunity lies in supplying vitamins, minerals, botanical extracts, probiotics and other scientifically validated actives to local and regional formulation partners. For finished-product companies, the opening is in branded supplements and OTC-adjacent health products that can satisfy registration requirements and align with pharmacy retail strategies.
Regulation remains a defining factor. Across the Eurasian Economic Union, authorities have been tightening traceability and compliance requirements for dietary supplements and health products, including moves toward unified marking systems and stronger state registration frameworks. While those requirements raise the cost of entry, they also favour manufacturers with established regulatory capabilities and high-quality production standards.
Uzbekistan is trying to leverage that regulatory shift alongside its geography. Located between South Asia, Russia and Central Asia, the country has been promoting pharmaceutical parks, foreign investment incentives and export-oriented manufacturing as part of its broader industrial development strategy.
Officials are positioning Tashkent not only as a domestic growth market but also as a logistical and regulatory gateway into surrounding CIS economies. The alignment with Nutrify Today and Pharma Eurasia is intended to reinforce that role by linking policy dialogue with commercial execution.
Under the proposed framework, Nutrify Today’s Sumflex and C-Suite Summit in Mumbai would continue to serve as a global leadership platform where regulators, investors and industry executives discuss policy and investment strategy. The commercial dimension of the corridor would then move to Tashkent through Pharma Eurasia 2026, scheduled for May 20–22, where companies are expected to pursue distribution agreements, regulatory engagement and regional partnerships.
Abdulla Azizov, First Deputy Minister of Health of Uzbekistan and chairman of the Pharmaceutical Industry Development Agency, said the country sees itself playing a strategic connecting role in regional healthcare trade. “Uzbekistan is poised to emerge as a strategic bridge between India and the CIS in pharmaceuticals and nutraceuticals. Through collaboration with Nutrify Today and Pharma Eurasia, we are institutionalising a transparent and technology-enabled trade ecosystem,” he said.
Khasim, executive director at Nutrify Today, said the dual-platform structure was designed to connect high-level strategy with practical market access. “With Sumflex anchoring global leadership in Mumbai and Pharma Eurasia providing the structured commercial platform in Tashkent, this initiative transforms vision into executable trade architecture,” he said.
For businesses evaluating Eurasia, the appeal of the region is becoming clearer. CIS markets are no longer viewed solely as secondary export destinations for excess inventory. Instead, they are evolving into a more structured consumer-health landscape where pharmacy chains are gaining influence, regulatory oversight is increasing and demand for science-backed health products continues to expand.
That transformation is attracting growing attention from pharmaceutical, nutraceutical and ingredient companies seeking new growth corridors beyond traditional Western markets.
Uzbekistan is betting that its combination of regulatory reform, geographic positioning and institutional partnerships will allow it to capture a central role in that evolving trade map — serving as a gateway through which Indian and global healthcare manufacturers can reach a rapidly developing Eurasian consumer-health market.
